Inserm Launches a Pilot of Labguru for Researchers Across the Institute
CAMBRIDGE, MA–(Marketwired – April 29, 2016) – Biodata, producer of Labguru is thrilled to announce that after a competitive tender process, Institut national de la santé et de la recherche médicale (Inserm) has selected Labguru for an institution-wide pilot of its integrated electronic lab notebook (ELN) and laboratory information management system (LIMS). The initial rollout will include implementation and training for users across 14 different research sites (including Paris, Lyon, and Strasbourg).
Inserm went through a competitive tender process and highlighted three themes that were critical to the selection process:
- Strict IT data compliancy: Inserm needed to have a secure system that could be deployed on servers in France
- Sharing: Inserm needed a strong system that allowed internal and external collaboration inside in labs
- Tractability and quality of the research data: Inserm wanted to implement a system that allowed researchers to have better tractability of their research. This is key in implanting a data quality policy for the Inserm Institute
Ultimately, after rigorous analysis and evaluation, they selected Labguru for a pilot phase that launched at the end of 2015. On why Inserm selected Labguru, Fanny Brizzi, Project Manager Inserm – Department of the Information System (DSI) said, “Labguru’s experience in Europe and track record of strong usage around the globe conveyed reliability and trust that Labguru could eventually sustain the 15,000 people that Inserm could potentially bring should the pilot be a success.”
Labguru gives Inserm researchers new ways to track, share, and organize their research data and their labs. Labs and researchers that implement Labguru realize better workflows; gather clearer feedback, save money and time leading to more research insights, faster. The software combines a flexible electronic lab notebook (ELN) with a biological and biochemical specimens tracking solution making it an ideal solution for the pre-clinical research environment.
Inserm is the largest human health and biological research institute in Europe and one of the most well respected research institutions on the planet. With a budget of 989 million euros in 2014, Inserm supports more than 300 laboratories across France. In total, the teams include nearly 15,000 researchers, engineers, technicians, post-doctoral students, etc.1 Moving to a digital platform ensures better data capture and on the choice of Labguru, Founder Jonathan Gross, said, “Inserm selected Labguru after a rigorous assessment of their needs and available solutions. Our approach comprising an integrated scientific research platform that currently enables multi-site collaboration, is resulting in measurable improvements in research data management, communication, and research continuity. We look forward to supporting Inserm’s bold vision of studying every disease.”
Major pharmaceutical organizations, biotechnology companies, research hospitals, individual academic labs, and independent research institutions trust Labguru’s tools.
About BioData
With offices in Boston, Austin, Tel Aviv, and London, BioData creates digital tools for increasing the productivity of academic and industry laboratories. Its flagship product, Labguru, is currently used by thousands of researchers in thousands of labs worldwide. Founded in 2007, BioData is a portfolio company of Digital Science and part of the Holtzbrinck Publishing Group. For more information, visit www.labguru.com.
About INSERM
Founded in 1964, the French National Institute of Health and Medical research (Inserm) is a public science and technology institute, jointly supervised by the French Ministry of National Education, Higher Education and Research and the Ministry of Social Affairs, Health and women’s Rights. Inserm is the only French public research institute to focus entirely on human health and positions itself on the pathway from research laboratory to the bed of the patient. The mission of its scientists is to study all diseases, from the most common to the rarest.
1 http://presse.inserm.fr/en/service-presse/inserm-en-bref/
